[177Lu]pertuzumab: experimental therapy of HER-2-expressing xenografts.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Cancer Research

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/0008-5472.CAN-06-2363PMID 17210714
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab

  2006cited by this paper
• The effectiveness of trastuzumab (Herceptin) combined with chemotherapy for gastric carcinoma with overexpression of the c-erbB-2 protein

  2005cited by this paper
• Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer.

  2005cited by this paper
• Analysis of HER2 expression in primary urinary bladder carcinoma and corresponding metastases

  2005cited by this paper
• [177Lu]pertuzumab: experimental studies on targeting of HER-2 positive tumour cells

  2005cited by this paper
• Signal transduction and oncogenesis by ErbB/HER receptors.

  2004cited by this paper
• Co-expression of ErbB-family members in human breast cancer: Her-2/neu is the preferred dimerization candidate in nodal-positive tumors.

  2004cited by this paper
• HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review

  2004cited by this paper
• A new therapeutic antibody masks ErbB2 to its partners.

  2004cited by this paper
• Role of HER2/neu in tumor progression and therapy.

  2004cited by this paper
• Role of HER receptors family in development and differentiation

  2004cited by this paper
• Tumour therapy with radionuclides: assessment of progress and problems.

  2003cited by this paper
• Biodistribution of the chimeric monoclonal antibody U36 radioiodinated with a closo-dodecaborate-containing linker. Comparison with other radioiodination methods.

  2003cited by this paper
• Biodistribution and Dosimetry of 177Lu-Labeled [DOTA0,Tyr3]Octreotate in Male Nude Mice with Human Small Cell Lung Cancer

  2003cited by this paper
• Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab

  2003cited by this paper
• Dosimetric comparison of radionuclides for therapy of somatostatin receptor-expressing tumors.

  2001cited by this paper
• Biomarker conservation in primary and metastatic epithelial ovarian cancer.

  2000cited by this paper
• Radiosensitivity patterns of four human ovarian cancer cell lines in vitro.

  1997cited by this paper
• Construction and characterization of the chimeric monoclonal antibody E48 for therapy of head and neck cancer

  1995cited by this paper
• MAb U36, a novel monoclonal antibody successful in immunotargeting of squamous cell carcinoma of the head and neck.

  1993cited by this paper
• Bone marrow dosimetry for radioimmunotherapy: theoretical considerations.

  1993cited by this paper
• Radiometal labeling of immunoproteins: covalent linkage of 2-(4-isothiocyanatobenzyl)diethylenetriaminepentaacetic acid ligands to immunoglobulin.

  1990cited by this paper

• Chlorambucil Conjugation Enhances the Potency of Rituximab: Synthesis and Evaluation of the Novel [177Lu]Lu-Labeled Rituximab-Chlorambucil Conjugate toward Therapy of Non-Hodgkin's Lymphoma.

  2025cites this paper
• Targeted Radionuclide Therapy Using a Lutetium-177 Labeled Human Anti-CD133 Antibody

  2025cites this paper
• Development of an in vivo ovarian cancer peritoneal carcinomatosis model for radioimmunotherapy testing.

  2025cites this paper
• Targeting HER2 in solid tumors: Unveiling the structure and novel epitopes.

  2024cites this paper
• Intricacies in the Preparation of Patient Doses of [^177Lu]Lu-Rituximab and [^177Lu]Lu-Trastuzumab Using Low Specific Activity [^177Lu]LuCl_3: Methodological Aspects

  2023cites this paper
• Design and construction of scFv-PE35KDEL as a novel immunotoxin against human epidermal growth factor receptor 2 for cancer therapy

  2023cites this paper
• Unravelling the potential of Lutetium-177 labeled pertuzumab targeting HER 2 receptors for theranostic applications.

  2022cites this paper
• Clinical Dose Preparation of [177Lu]Lu-DOTA-Pertuzumab Using Medium Specific Activity [177Lu]LuCl3 for Radioimmunotherapy of Breast and Epithelial Ovarian Cancers, with HER2 Receptor Overexpression

  2022cites this paper
• Radiolabeled Antibodies for Cancer Imaging and Therapy

  2022cites this paper
• Monoclonal antibody based radiopharmaceuticals for imaging and therapy.

  2021cites this paper
• HER2-directed antibodies, affibodies and nanobodies as drug-delivery vehicles in breast cancer with a specific focus on radioimmunotherapy and radioimmunoimaging

  2020cites this paper
• Targeting HER2 in Nuclear Medicine for Imaging and Therapy

  2018cites this paper
• Translation and Development of Molecular Imaging Probes for Detecting Response of Breast Cancer to Trastuzumab

  2017cites this paper
• Emerging drugs targeting human epidermal growth factor receptor 2 (HER2) in the treatment of breast cancer

  2016cites this paper
• PET Imaging of Tissue Factor in Pancreatic Cancer Using 64Cu-Labeled Active Site–Inhibited Factor VII

  2016cites this paper
• Targeted delivery of immunomodulatory proteins: evaluation of novel antibody-chemokine and antibody-cytokine fusion proteins for cancer therapy

  2015cites this paper
• Preclinical pharmacokinetics, biodistribution, radiation dosimetry and acute toxicity studies required for regulatory approval of a Clinical Trial Application for a Phase I/II clinical trial of (111)In-BzDTPA-pertuzumab.

  2015cites this paper
• EGFR-expression in primary urinary bladder cancer and corresponding metastases and the relation to HER2-expression. On the possibility to target these receptors with radionuclides

  2015cites this paper
• D-Amino acid peptide residualizing agents bearing N-hydroxysuccinimido- and maleimido-functional groups and their application for trastuzumab radioiodination.

  2015cites this paper
• Comparative Efficacy of 177Lu and 90Y for Anti-CD20 Pretargeted Radioimmunotherapy in Murine Lymphoma Xenograft Models

  2015cites this paper
• Lutetium-177 therapeutic radiopharmaceuticals: linking chemistry, radiochemistry, and practical applications.

  2015cites this paper
• Nouvelles approches thérapeutiques dans le cancer du sein HER2 positif

  2015cites this paper
• Lutetium-177 complexation of DOTA and DTPA in the presence of competing metals

  2015cites this paper
• Biodistribution and radiation dosimetry of radioiodinated hypericin as a cancer therapeutic.

  2014cites this paper
• Affinity enhancement of HER2-binding Z(HER2:342) affibody via rational design approach: a molecular dynamics study

  2014cites this paper
• Production of highly purified no-carrier-added 177Lu for radioimmunotherapy

  2014cites this paper
• Emerging classes of armed antibody therapeutics against cancer

  2014cites this paper
• Evaluation of 89Zr-pertuzumab in Breast Cancer Xenografts

  2014cites this paper
• HER2 expression in primary gastric cancers and paired synchronous lymph node and liver metastases. A possible road to target HER2 with radionuclides

  2014cites this paper
• Improved Tumor Targeting of Anti-HER2 Nanobody Through N-Succinimidyl 4-Guanidinomethyl-3-Iodobenzoate Radiolabeling

  2014cites this paper
• An overview of translational (radio)pharmaceutical research related to certain oncological and non-oncological applications.

  2013cites this paper
• Distribution and accumulation of Cy5.5-labeled thermally cross-linked superparamagnetic iron oxide nanoparticles in the tissues of ICR mice

  2013cites this paper
• The new golden era for radioimmunotherapy: not just for lymphomas anymore.

  2013cites this paper
• Comparing high LET 227Th- and low LET 177Lu-trastuzumab in mice with HER-2 positive SKBR-3 xenografts.

  2013cites this paper
• Preclinical evaluation of 227Th-labeled and 177Lu-labeled trastuzumab in mice with HER-2-positive ovarian cancer xenografts

  2012cites this paper
• New peptide receptor radionuclide therapy of invasive cancer cells: in vivo studies using 177Lu-DOTA-AE105 targeting uPAR in human colorectal cancer xenografts.

  2012cites this paper
• Potential for clinical radionuclide-based imaging and therapy of common cancers expressing EGFR-family receptors

  2012cites this paper
• HER2 as a Therapeutic Target in Ovarian Cancer

  2012cites this paper
• Intraperitoneal Radionuclide Therapy – Clinical and Pre-Clinical Considerations

  2012influential citation
• Experimental Radionuclide Therapy of HER2-Expressing Xenografts Using Two-Step Targeting Nuclisome Particles

  2012cites this paper
• Pre-Clinical Assessment of 177Lu-Labeled Trastuzumab Targeting HER2 for Treatment and Management of Cancer Patients with Disseminated Intraperitoneal Disease

  2011cites this paper
• The best radionuclide for radioimmunotherapy of small tumors: beta- or alpha-emitter?

  2011cites this paper
• Radioimmunotherapy of solid tumors: searching for the right target.

  2011cites this paper
• Influence of an aliphatic linker between DOTA and synthetic Z(HER2:342) Affibody molecule on targeting properties of the (111)In-labeled conjugate.

  2011cites this paper
• 177Lu-immunotherapy of experimental peritoneal carcinomatosis shows comparable effectiveness to 213Bi-immunotherapy, but causes toxicity not observed with 213Bi

  2011cites this paper
• Intraperitoneal Alpha-Radioimmunotherapy of Advanced Ovarian Cancer in Nude Mice Using Different High Specific Activities

  2010cites this paper
• Synthesis and biodistribution studiesof 177Lu-trastuzumab as a therapeutic agent in the breast cancer mice model

  2010cites this paper
• Affibody molecules: Engineered proteins for therapeutic, diagnostic and biotechnological applications

  2010cites this paper
• Discovery of epitopes for targeting the human epidermal growth factor receptor 2 (HER2) with antibodies

  2009cites this paper
• Influence of valency and labelling chemistry on in vivo targeting using radioiodinated HER2-binding Affibody molecules

  2009cites this paper
• Imaging of HER-2 overexpression in tumors for guiding therapy.

  2008cites this paper
• Therapy of human carcinoma xenografts with antibodies to EGFr and HER-2 conjugated to radionuclides emitting low-energy electrons

  2008cites this paper
• Her2-positive breast cancer: herceptin and beyond.

  2008cites this paper
• In vivo and in vitro uptake of 111In, delivered with the affibody molecule (ZEGFR:955)2, in EGFR expressing tumour cells.

  2008cites this paper
• Zielgerichtete Radionuklidtherapie mit α-Emittern - Grundlagen, experimentelle und erste klinische Studien

  2008cites this paper
• EGFR-Family Expression and Implications for Targeted Radionuclide Therapy

  2008cites this paper
• Targeted Radionuclide Tumor Therapy

  2008cites this paper
• Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule.

  2007cites this paper
• List of Papers Abbreviations Ai Accumulation Index Amm Ammonium Sulphate Buffer Cryo-tem Cryogenic Transmission Electron Micros- Copy Dhsm Dihydrosphingomyelin Dsb Double-strand Break Dspc Distearoylphosphatidylcholine Dspe Distearoylphosphatidylethanolamine Egf Epidermal Growth Factor Egfr Epiderma

  year unknowncites this paper